Akcea Therapeutics (Akcea Therapeutics) Sale Of Investment : $215.6 Mil (TTM As of Jun. 2020)

View and export this data going back to 2017. Start your Free Trial

What is Akcea Therapeutics Sale Of Investment?

Akcea Therapeutics's sale of investment for the three months ended in Jun. 2020 was $64.8 Mil. It means Akcea Therapeutics gained $64.8 Mil from selling investments. Akcea Therapeutics's sale of investment for the trailing twelve months (TTM) ended in Jun. 2020 was $215.6 Mil.

Compared with last quarter ($53.8 Mil in Mar. 2020 ), Akcea Therapeutics gained more money from selling investments in Jun. 2020 ($64.8 Mil).

Akcea Therapeutics Sale Of Investment Historical Data

The historical data trend for Akcea Therapeutics's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akcea Therapeutics Sale Of Investment Chart

Akcea Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Sale Of Investment

Get a 7-Day Free Trial

0.96

51.46

98.78

208.56

197.01

Akcea Therapeutics Quarterly Data
	Dec14	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Sale Of Investment	Get a 7-Day Free Trial															40.35	55.26	41.71	53.80	64.84

Akcea Therapeutics Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $215.6 Mil.

Akcea Therapeutics Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Akcea Therapeutics's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Akcea Therapeutics (Akcea Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akcea Therapeutics Inc (NAS:AKCA) » Definitions » Sale Of Investment

Comparable Companies

Traded in Other Exchanges

N/A

Address

22 Boston Wharf Road, 9th Floor, Boston, MA, USA, 02110

Website

https://www.akceatx.com

Akcea Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.

Executives

Michael J. Yang	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Joseph Iii Klein	director	C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Sandford D Smith	director	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
B Lynne Parshall	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Joshua F. Patterson	officer: General Counsel	C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Damien Mcdevitt	director, officer: Chief Executive Officer	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Alex G. Howarth	officer: Chief Operating Officer	C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Kyle Jenne	officer: Chief Commercial Officer	C/O AKCEA THERAPEUTICS, INC. 22 BOSTON WHARF ROAD, 9TH FLOOR BOSTON MA 02210
William T. Andrews	officer: Chief Medical Officer	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Barbara Yanni	director	1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Michael Dennis Price	officer: Chief Financial Officer
Elaine Hochberg	director	C/O AKCEA THERAPAEUTICS 55 CAMBRIDGE PKWY, STE 100 CAMBRIDGE MA 02142
Isis Pharmaceuticals Inc	10 percent owner	2855 GAZELLE COURT, CARLSBAD CA 92010
Michael F Maclean	officer: Chief Financial Officer	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Paula Soteropoulos	director, officer: Chief Executive Officer	49 WINONA STREET, PEABODY MA 01960